Evidence map›Paper›PMID 40291168›Full record

ArticlePCN reports : psychiatry and clinical neurosciences2025

Olanzapine enabled rechallenge after lorlatinib-induced psychosis: A case report.

Akiyoshi Yokode, Masaki Fujiwara, Yuko Nakamura, Kadoaki Ohashi, Shinji Sakamoto, Manabu Takaki

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PCN reports : psychiatry and clinical neurosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Olanzapine enabled rechallenge after lorlatinib-induced psychosis: A case report.PCN reports : psychiatry and clinical neurosciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Akiyoshi YokodeDepartment of Neuropsychiatry Okayama University Hospital Okayama Japan.
Masaki FujiwaraDepartment of Neuropsychiatry Okayama University Hospital Okayama Japan.ORCID 0000-0002-6181-3166
Yuko NakamuraDepartment of Neuropsychiatry Okayama University Hospital Okayama Japan.
Kadoaki OhashiDepartment of Respiratory Medicine Okayama University Hospital Okayama Japan.
Shinji SakamotoDepartment of Neuropsychiatry Okayama University Hospital Okayama Japan.
Manabu TakakiDepartment of Neuropsychiatry Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences Okayama Japan.ORCID 0000-0002-7371-2821

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Lorlatinib is a third-generation tyrosine kinase inhibitor for anaplastic lymphoma kinase ( Case Presentation: A 32-year-old woman with Conclusion: Lorlatinib is an essential drug for controlling brain metastases in

Indexed as

lorlatiniblung cancermedication‐induced psychosispsycho‐oncology

Identifiers

PMID40291168
PMCPMC12034264

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.